What Did You Miss in 2026?
The 4th Viral Vector Process Development & Manufacturing Summit returned to Boston and brought together the global community redefining scalable, safe, and cost-efficient viral vector production.
The 2026 program featured two days of cutting-edge discussions, technical case studies, and collaborative roundtables focused on driving down COGs, improving analytical precision, and enabling regulatory readiness. By addressing these core challenges head-on, attendees uncovered practical strategies to make vector manufacturing more cost-efficient, reproducible, and compliant with safety standards – ultimately accelerating time to marker, ensuring consistent product quality at scale and strengthening the commercial viability of advanced cell and gene therapy programs.
Attendees walked away with practical solutions to streamline upstream and downstream workflows, harness automation and digital analytics for GMP scalability, and stay ahead of shifting global regulatory and pharmacopeial standards.
2026 Highlights
Driving Down the Cost of Goods
Learn from Ultragenyx, Sanofi, and Cabaletta Bio as they reveal practical strategies to reduce plasmid dependency, improve upstream yield, and simplify raw-material supply chains - unlocking scalable, low-cost viral vector manufacturing.
Strengthening Process Consistency & Regulatory Readiness
Hear directly from NCI, USP, and leading CMC experts on establishing robust QC and analytical frameworks to ensure batch-to-batch reproducibility, safety, and alignment with evolving global guidance.
Reconnect, Collaborate & Expand Your Network
Engage in over six hours of structured networking, including roundtable discussions and speed networking, designed to spark collaboration and build lasting partnerships across biopharma, CDMOs, and regulatory peers.
Attending Companies Included